Methadone Half-Life
Methadone has a plasma elimination half-life that averages approximately 24 hours, with a wide range of 8 to 59 hours (and in some cases extending beyond 100 hours), reflecting marked interindividual variability. 1
Key Pharmacokinetic Characteristics
The elimination half-life of methadone demonstrates substantial variability across individuals:
- Average half-life: ~22-24 hours 2, 1
- Reported range: 8-59 hours in most studies 1
- Extended range: Can reach 15-120 hours in certain individuals 3, 4
- For R-enantiomer (the active form): Mean values around 40 hours 5
Critical Clinical Implications
The discrepancy between methadone's analgesic duration (4-8 hours) and its elimination half-life creates significant safety concerns. 2, 1
Why This Matters for Patient Safety:
- Delayed steady-state: Full analgesic effects and steady-state plasma concentrations typically require 3-5 days of dosing 1
- Drug accumulation: With repeated dosing, methadone accumulates in the liver and is slowly released, prolonging duration of action despite low plasma concentrations 1
- Peak respiratory depression: Occurs later and persists longer than peak analgesic effects 6, 1
- Incomplete cross-tolerance: High opioid tolerance does NOT eliminate overdose risk 1
Dosing Frequency Implications:
Given the long half-life, methadone should not be dosed more frequently than every 8 hours to avoid accumulation and adverse effects 2. For chronic pain management, typical dosing is every 8-12 hours 3.
Factors Contributing to Variability
The 17-fold interindividual variation in methadone blood concentrations for a given dose 5 stems from:
- Genetic polymorphisms in CYP450 enzymes (primarily CYP3A4, CYP2B6, CYP2C19) 1, 5
- Hepatic metabolism differences between fast and slow metabolizers 7
- Protein binding variations (85-90% bound to α1-acid glycoprotein) 1, 5
- Urinary pH changes affecting renal clearance 8
Special Populations
Pregnancy: Terminal half-life decreases during second and third trimesters, with increased clearance potentially leading to withdrawal symptoms; dosage increases or shorter intervals may be needed 1
Renal/hepatic impairment: Risk of drug accumulation to toxic levels with prolonged persistence in the body 6
Common Pitfall
Deaths have occurred during treatment initiation due to cumulative effects over the first several days, before steady-state is reached 1. The most dangerous period is days 1-5 when clinicians and patients may not appreciate that drug is still accumulating despite stable dosing.